Novartis says in the article below: "Locametz is expected to be available to physicians and patients within weeks." I would assume Novartis would have all bases covered, from manufacture to distribution.
It is really troubling to see Telix directly compete with Novartis for imaging since Novartis is likely to take the lions share of the market (US, EU and AU). I wasn't aware Novartis were also applying for approval for an imaging agent until last week, so this is a new but very significant revelation to me. It would be good to get clarification from TLX about this approval.
Good luck to all.
https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer
How low will it go?, page-102
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.98 |
Change
-0.490(2.09%) |
Mkt cap ! $7.691B | |||
| Open | High | Low | Value | Volume |
| $23.25 | $23.36 | $22.78 | $32.40M | 1.409M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $22.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.99 | 421 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |